The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of -5.67 is in distress zone. This implies bankruptcy possibility in the next two years.
Caribou Biosciences has a Altman Z-Score of -5.60, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Caribou Biosciences's Altman Z-Score or its related term are showing as below:
CRBU'
s Altman Z-Score Range Over the Past 10 Years
Min: -5.67 Med: 1.66 Max: 15.36
Current: -5.67
During the past 7 years, Caribou Biosciences's highest Altman Z-Score was 15.36. The lowest was -5.67. And the median was 1.66.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Caribou Biosciences Altman Z-Score Related Terms
Caribou Biosciences Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Caribou Biosciences's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRBU vs YDES, PRQR, CRBP: Altman Z-Score Comparison
For the Biotechnology subindustry, Caribou Biosciences's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caribou Biosciences Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Caribou Biosciences's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Caribou Biosciences's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.6893
+
1.4
*
-4.1719
+
3.3
*
-0.8978
+
0.6
*
3.8422
+
1.0
*
0.0752
=
-5.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Caribou Biosciences (CRBU) has a Altman Z-Score of -5.60 as of Jul. 02, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Caribou Biosciences and its competitors. According to the industry distribution chart, Caribou Biosciences ranks #776 out of 929 companies in the Biotechnology industry, placing it in the top 83.5%.
Is Caribou Biosciences' Altman Z-Score too high?
Caribou Biosciences' current Altman Z-Score is -5.60. Based on the distribution chart, Caribou Biosciences ranks #776 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caribou Biosciences has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Altman Z-Score compare to YDES and PRQR?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #776 out of 929 companies for Altman Z-Score. This places Caribou Biosciences in the lower half of its industry. The industry median Altman Z-Score is 2.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.61, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Caribou Biosciences and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current Altman Z-Score is -5.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.69, compared to a current price of $1.82 — trading 7.7% above its estimated fair value. The current Altman Z-Score is -5.60. Caribou Biosciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Altman Z-Score is -5.60 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caribou Biosciences (CRBU) Overvalued in 2026?
Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued.
The current stock price of $1.82 is trading 7.7% above its estimated GF Value™ of $1.69.
GuruFocus considers Caribou Biosciences to be Fairly Valued.
Key valuation signals for CRBU:
Altman Z-Score: -5.60
GF Value™: $1.69 vs. price of $1.82 (7.7% above fair value)
No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score
Get the complete analysis for CRBU
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRBU has been successfully added to your 
